In an infant with cytomegalovirus infection receiving valganciclovir, what are the possible etiologies of isolated anemia?

Possible Etiologies for Pure Anemia in an Infant with CMV on Valganciclovir

The most likely cause of isolated anemia in an infant receiving valganciclovir for CMV is drug-induced myelosuppression, though CMV itself can cause pure red cell aplasia and other underlying causes must be excluded.

Primary Consideration: Valganciclovir-Induced Myelosuppression

Valganciclovir's major adverse effect is myelosuppression, specifically causing anemia, neutropenia, and thrombocytopenia 1, 2. The FDA drug label clearly states that severe anemia has been reported in patients treated with valganciclovir 2. In clinical trials of infants with symptomatic congenital CMV:

• Approximately two-thirds of infants developed substantial neutropenia during ganciclovir therapy 1
• Anemia occurred in 31% of pediatric solid organ transplant patients on valganciclovir 2
• Dose reduction or interruption was necessary in up to 40% of patients due to hematologic toxicity 1

Important caveat: While valganciclovir typically causes pancytopenia (affecting all cell lines), isolated anemia can occur, particularly early in treatment or with lower drug exposure affecting primarily the red cell line.

CMV-Related Pure Red Cell Aplasia

CMV infection itself can cause pure red cell aplasia (PRCA) in infants 3. A case report documented a 3-month-old infant with severe anemia due to PRCA secondary to congenital CMV infection, which responded to ganciclovir treatment 3. This represents a paradoxical situation where:

• The underlying CMV infection causes PRCA
• The treatment (valganciclovir) can also cause anemia
• Distinguishing between these requires bone marrow examination showing absent or markedly reduced erythroid precursors with preserved myeloid and megakaryocytic lines

Additional Etiologies to Consider

Congenital CMV Disease Manifestations

CMV disease commonly presents with anemia as part of the clinical syndrome 4:

• Anemia occurred in 53% of infants with congenital CMV in one series 4
• Often accompanied by hepatosplenomegaly, jaundice, and thrombocytopenia 4

Gastrointestinal Blood Loss

CMV can cause gastrointestinal manifestations leading to chronic blood loss 5:

• CMV colitis, gastritis, or esophageal ulcers
• May present with melena or occult bleeding
• Requires endoscopic evaluation with biopsy and CMV PCR 5

Hemolytic Anemia

• CMV-associated immune-mediated hemolysis
• Check reticulocyte count, LDH, haptoglobin, direct antiglobulin test

Nutritional Deficiencies

• Iron deficiency from chronic disease or blood loss
• Folate or B12 deficiency (less common in infants)

Concurrent Infections

• Parvovirus B19 (causes PRCA)
• Other viral infections affecting erythropoiesis

Diagnostic Approach

To differentiate between etiologies, obtain:

1. Complete blood count with differential and reticulocyte count

   • Isolated anemia with normal WBC/platelets suggests PRCA or hemolysis
   • Pancytopenia suggests drug toxicity
   • Elevated reticulocytes suggest hemolysis or blood loss

2. Peripheral blood smear

   • Assess for hemolysis, red cell morphology

3. Iron studies, folate, B12

   • Rule out nutritional causes

4. Hemolysis workup if indicated

   • LDH, haptoglobin, indirect bilirubin, DAT

5. Stool guaiac testing

   • Assess for GI blood loss

6. Bone marrow examination if diagnosis unclear

   • PRCA shows absent/reduced erythroid precursors with normal other lineages
   • Drug-induced shows hypocellularity affecting multiple lineages

7. Valganciclovir drug levels if available

   • Recent data shows preterm/low birthweight infants achieve higher drug concentrations than term infants 6
   • Higher Cmin associated with increased adverse effects 6

Management Considerations

If drug-induced anemia is suspected:

• Monitor CBC frequently (at least weekly) 2
• Consider dose reduction if hemoglobin <8 g/dL 2
• Temporary drug interruption may be necessary
• G-CSF can ameliorate marrow suppression but primarily affects neutrophils 1
• Transfusion support as needed

Critical monitoring point: Complete blood counts with differential and platelet counts should be performed frequently, especially in patients with pre-existing cytopenias 2. Cytopenia may occur at any time during treatment and may worsen with continued dosing, though cell counts usually begin to recover within 3-7 days after discontinuing the drug 2.